文
论文分享
演练场
杂货铺
论文推荐
字
编辑器下载
登录
注册
M. Pishvain
发表
Abstract CT023: Phase I results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events
N. Rizvi, H. Kluger, M. Callahan, 2016 .